John Renger
Director Técnico/Científico/I+D en CEREVEL THERAPEUTICS HOLDINGS, INC. .
Fortuna: 259 514 $ al 31/05/2024
Perfil
En la actualidad, John Renger es director científico de Cerevel Therapeutics Holdings, Inc. En el pasado, el Dr. Renger fue Vicepresidente Asociado en Merck & Co., Inc. y Vicepresidente de Investigación y Desarrollo en Imbrium Therapeutics LP. Se doctoró y se licenció en la Universidad de Iowa.
Participaciones conocidas en empresas públicas
Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
---|---|---|---|---|
31/03/2024 | 6 370 ( 0.00% ) | 259 514 $ | 31/05/2024 |
Cargos activos de John Renger
Empresas | Cargo | Inicio |
---|---|---|
CEREVEL THERAPEUTICS HOLDINGS, INC. | Director Técnico/Científico/I+D | 01/05/2019 |
Antiguos cargos conocidos de John Renger.
Empresas | Cargo | Fin |
---|---|---|
Purdue Pharma LP
Purdue Pharma LP Pharmaceuticals: MajorHealth Technology Purdue Pharma LP engages in the development and provision of prescription medicines. It offers a portfolio of medical products in categories, including prescription opioids, sleep, laxatives, antiseptics, and dietary supplement. The company was founded by Raymond R. Sackler in 1991 and is headquartered in Stamford, CT. | Corporate Officer/Principal | 01/04/2018 |
MERCK & CO., INC. | Corporate Officer/Principal | 01/08/2016 |
Imbrium Therapeutics LP
Imbrium Therapeutics LP Pharmaceuticals: MajorHealth Technology Part of Purdue Pharma LP, Imbrium Therapeutics LP is a clinical-stage biopharmaceutical company based in Stamford, CT. The company is dedicated to advancing medical science through the development of important new pharmacologic and biologic therapeutics. Imbrium is pursuing oncology chemotherapeutics, treatments for disorders of the central nervous system, and non-opioid approaches to the management of pain. The company strives to develop and bring to market new medicines that serve the unmet needs of patients, physicians, and health systems worldwide. Imbrium has built a robust and diversified pipeline of investigational drug candidates, and actively collaborates with industry and academic partners to identify and advance future impactful medicines. | Director Técnico/Científico/I+D | - |
Formación de John Renger.
University of Iowa | Doctorate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
Empresas cotizadas | 2 |
---|---|
MERCK & CO., INC. | Health Technology |
CEREVEL THERAPEUTICS HOLDINGS, INC. | Health Technology |
Empresas privadas | 2 |
---|---|
Purdue Pharma LP
Purdue Pharma LP Pharmaceuticals: MajorHealth Technology Purdue Pharma LP engages in the development and provision of prescription medicines. It offers a portfolio of medical products in categories, including prescription opioids, sleep, laxatives, antiseptics, and dietary supplement. The company was founded by Raymond R. Sackler in 1991 and is headquartered in Stamford, CT. | Health Technology |
Imbrium Therapeutics LP
Imbrium Therapeutics LP Pharmaceuticals: MajorHealth Technology Part of Purdue Pharma LP, Imbrium Therapeutics LP is a clinical-stage biopharmaceutical company based in Stamford, CT. The company is dedicated to advancing medical science through the development of important new pharmacologic and biologic therapeutics. Imbrium is pursuing oncology chemotherapeutics, treatments for disorders of the central nervous system, and non-opioid approaches to the management of pain. The company strives to develop and bring to market new medicines that serve the unmet needs of patients, physicians, and health systems worldwide. Imbrium has built a robust and diversified pipeline of investigational drug candidates, and actively collaborates with industry and academic partners to identify and advance future impactful medicines. | Health Technology |
- Bolsa de valores
- Insiders
- John Renger